“We are strongly entering Brazil and Mexico,” says Sorrento Therapeutics CEO

In October 2020, Brazil's health regulator ANVISA authorized the company to begin phase 2 trials of the antibody-based drug in Brazil, with about 400 volunteers.

RIO DE JANEIRO, BRAZIL - Sorrento Therapeutics, a biotech company based in San Diego (USA), which is developing an antibody treatment against Covid-19, will be stepping firmly into markets of countries like Brazil and Mexico, said the company's CEO Henri Ji.

As certain countries are experiencing greater logistical challenges to administer vaccines, which often require very cold temperatures, opportunities are emerging for companies developing treatments and prophylactics that are easier to transport and store, he said.

"These countries need an alternative," said Henri Ji, the company's CEO.

The emergence of new and dangerous SARS-CoV-2 variants has . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?